In this study, we investigated the in vitro and in vivo efficacy of Fas ligand (FasL) gene therapy for the treatment of head and neck cancer. Three head and neck squamous cell carcinoma (HNSCC) cell lines (SCC-1, SCC-12, and SCC-14a) were treated with the Fas agonist CH-11, a monoclonal antibody to the Fas receptor, or with a replication-incompetent adenovirus (AdGFPFasL) expressing a modified murine Fas ligand gene fused to green fluorescent protein (GFP). A replication-incompetent adenovirus containing the GFP gene alone was used as a control for viral transduction toxicity (AdGFP). Cell death was quantified using a tetrazolium-based (MTS) assay. Cells were analyzed by flow cytometry to determine the expression of adenoviral and Fas receptors on the surface of the cells. Our results showed that the head and neck cancer cell lines are resistant to cell death induction when treated with the anti-Fas monoclonal antibody CH-11. This resistance can be overcome with AdGFPFasL, which was able to induce cell death in all three cell lines. Apoptosis induction was demonstrated using Western blotting by evaluating poly(ADP-ribose) polymerase, and caspase 9 cleavages. In addition, intratumoral injections of AdGFPFasL into SCC-14a xenografts induced significant growth suppression of tumors, indicating that FasL gene therapy may provide a new efficient therapeutic modality for HNSCC that is worthy of a clinical trial.
Introduction
The incidence of head and neck squamous cell carcinoma (HNSCC) is estimated to be more than 40 000 cases per year in the United States and worldwide around 500 000 cases annually. 1 Despite significant advances in diagnosis and treatment, 5-year survival of head and neck cancer patients has not appreciably improved. 2 Therefore, novel approaches are worth investigation in order to provide a more effective treatment for this challenging disease. One novel approach that is beginning to show promise for treatment of cancer involves gene therapy. Gene therapy has been continuously advancing since the first trial occurred in 1990 at the National institute of Health. 3 As of January 2005, there were 1020 approved gene therapy protocols in the USA and 675 of them were devoted to cancer treatment protocols. 3 The present report describes our investigation of the potential use of Fas ligand (FasL) gene therapy for the treatment of head and neck cancer.
One common feature of all cancers is their ability to escape apoptosis. Our main objective using FasL gene therapy is to express, in tumor cells, a mouse FasL gene introduced with a complex adenovirus to cause apoptosis in the tumor. Briefly, Fas (CD95/APO-1) is a 45 kDa membrane receptor in the TNF/NGF (nerve growth factor) superfamily. 4, 5 Fas ligand (FasL/CD95L/APO-1L) is a 40 kDa type II membrane protein in the TNF (tumor necrosis factor) family. 6, 7 The binding of FasL to Fas initiates a series of cellular events beginning with receptor clustering and ending up with induction of apoptosis leading to cell death. 8 In fact, several groups including our laboratory have investigated the use of Fas system activation in the treatment of cancer. This has been studied in multiple cell types including glioblastoma, prostate, bladder, and nasopharyngeal cancers. [9] [10] [11] [12] Unfortunately, due to liver toxicity, none of these approaches are suitable for systemic application. Therefore, a more realistic approach is to directly deliver the FasL gene to tumor cells, which would theoretically lead to minimum systemic leakage and consequently fewer side effects. Squamous cell cancers of the head and neck (HNSCC) have features that make them an attractive target for this intratumoral gene delivery approach. First, most HNSCC occur on mucosal surfaces of the oral cavity and oropharynx and can be directly visualized without the use of invasive procedures. Second, even when tumors metastasize to regional lymph nodes, they tend to remain near the original site of presentation and easily accessible for needle injection. Finally, recurrent tumors that arise following standard therapies, (basically the main target for Phase I clinical cancer gene therapy trials), are usually seen in the head and neck region and remain readily accessible to intratumoral injection allowing direct access and measurement of response. Taken together, these characteristics make HNSCC an excellent target for local intratumoral gene delivery and monitoring. 13 In fact, many gene therapy applications for HNSCC have proven to be quite efficient in animal models with a number advancing into clinical trials. In the USA, Introgen Therapeutics, Inc. has developed adenoviral p53 gene therapy, (INGN 201 (Advexin)), which is currently undergoing clinical development for the treatment of head and neck cancer. 3 In China a similar p53 adenovirus, Gendicine, was approved in 2003 and became the first commercially available gene medicine registered for treatment of nasopharyngeal cancer. 11 However, a problem that remains to be resolved in order to make cancer gene therapy more efficient is the issue of delivery. This limitation can be overcome using FasL gene therapy thanks to a bystander effect already described by use in a prostate cancer model. 14 For effective tumor reduction, the bystander effect is required due to low adenoviral transduction efficiency. Cells that undergo apoptosis release apoptotic vesicles that are able, on their own, to induce FasL-mediated apoptosis in nearby cells. In this study, we show that inducing Fasmediated apoptosis in HNSCC is a promising new therapeutic approach, which also elicits bystander activity. We believe that this new application of FasL therapy will facilitate development of FasL as an effective HNSCC gene therapy agent.
Materials and methods

Cell lines and culture
The HNSCC lines SCC-14a, SCC-1, and SCC-12 were acquired from Dr Thomas E Carey (University of Michigan, Ann Arbor, MI), and were maintained in DMEM 1X MOD medium with L-Glutamine and 4.5 g/l glucose (Media-tech, Herndon, VA). The human T cell Leukemia Jurkat cell line was acquired from Dr Yusuf Hannun (Medical University of South Carolina, Charleston, SC) and was maintained in RPMI-1640 medium (Media-tech, Herndon, VA) supplemented with 10% heat inactivated fetal bovine serum (FBS) (Hyclone, Logan, UT).
Reagents
The mouse anti-Fas monoclonal antibody CH-11 (Upstate, Lake Placid, NY) was used as a Fas agonist. Preparation and construction of the AdGFPFasL and AdGFP adenoviral vectors were previously described. 12 Antibodies for immunoblotting were as follows: conjugated anti-rabbit IgG-HRP 1:50 000 (Santa Cruz), conjugated anti-mouse IgG1 1:5000 (Santa Cruz), anti-PARP rabbit polyclonal 1:4000 (Santa Cruz), anti-actin rabbit polyclonal 1:1000 (Sigma, St Louis, MO), and anticaspase 9 rabbit polyclonal 1:1000 (New England BioLabs, Beverly, MA). 
Cytotoxicity assay
Generating bystander material
Bystander material was generated as previously described. 12 Briefly, HNSCC were infected with AdGFPFasL at MOI 50 in 100 mm plates for 16 h. The culture medium containing the floating debris and apoptotic bodies was harvested and centrifuged at 2000 g for 10 min. Following centrifugation, the pellet (P) fraction was washed twice with PBS, resuspended in 10 ml of complete medium and stored at À801C. The remaining adherent cells were washed once with PBS and lifted using trypsin-free chelating solution. Both the wash and the lifted cells pool (P) are centrifuged at 2000 g for 10 min. The resulting pellet (PT) was resuspended in 10 ml complete medium, aliquoted, and stored at À801C.
MTS assay for bystander material (PT) HNSCC cells (5 Â 10
3 ) were seeded and left overnight to attach. PT material containing the apoptotic bodies and cellular debris was preincubated for 1 h at room temperature with 26 ng/ml 1D6.14 fiber knob specific monoclonal antibody to prevent residual viral infection (kindly provided by Dr Joanne Douglas) and then coincubated with target cells and 5 mg/ml doxycycline for 24 h (Doxycycline prevents FasL expression from our adenovirus 15 ). Cells were examined by fluorescent microscopy and the MTS assay was used to quantitate cell death according to the manufacturer's protocol from the formula: [(1À(OD 490 of treated cells/OD 490 of untreated cells)) Â 100%].
Immunoblot analysis UM-SCC (7.5 Â 10 5 ) cells were seeded in DMEM/10% FBS overnight in 60 mm 2 tissue culture plates (Greiner Bio-One, Longwood, FL). Cells were treated with AdGFPFasL or AdGFP for 24 h. Following treatment, cellular protein was harvested at the indicated time points. Protein isolation and immunoblotting were performed as previously described. 16 Animal studies Animal experiments were carried out in accordance with both institutional and National Institutes of Health animal care regulations. Nu/Nu athymic nude mice were kept in a pathogen-free environment. SCC-14a was seeded in 150 mm 2 plates overnight to reach 70-80% confluence and harvested using cell stripper after washing with PBS. Cells were washed twice with PBS and centrifuged at 500 g Â 5 min and resuspended in serumfree media (SFM) at a concentration of 1 Â 10 7 /100 ml. One hundred microliters of suspended cells were injected subcutaneously into the right flank of the nude mouse. Animals were monitored weekly twice for tumor growth. When tumors appeared, their size was followed in three perpendicular dimensions using calipers and described as the tumor volume (mm 3 ) calculated using the formula [p/6 Â height (h) Â width (w) Â length (l)]. When tumor size reached 70-100 mm 3 , treatment with AdGFPFasL or control (PBS) was initiated. AdGFPFasL (10 9 IU) was injected in different sites of the tumor in 30 ml volumes. Injection was carried out every 72 h for four injections. Animals were killed when the tumor reached 2000 mm 3 .
Statistical analysis
Data in figures and graphs were performed in triplicate unless otherwise stated with results expressed as the mean7s.d. Animal studies were analyzed using ANOVA. A P-value of o0.001 was considered significant.
Results
Human HNSCC express surface Fas receptors but are generally resistant to CH-11 induced killing Three HNSCC lines were analyzed by Flow Cytometry Analysis using the monoclonal Fas agonistic antibody CH-11. As shown in Figure 1a , all cell lines examined expressed Fas on the cell surface with mean fluorescence of 21.1, 22.6, and 76.7 for UM-SCC-12, UM-SCC-14A, and UM-SCC-1, respectively. To determine if HNSCC were susceptible to CH-11, cells were incubated with CH-11 for 48 h at a concentration of 1 mg/ml, and assayed for cell death using the MTS assay. The Jurkat T-cell leukemia line was used as a positive control. As shown in Figure 1b , Jurkat cells were very sensitive to CH-11 induced death whereas HNSCC cell lines were variably resistant. UM-SCC-14A showed the most sensitivity at 32%. No observable correlation was found between FasR expression and sensitivity to CH-11.
AdGFPFasL transduction to HNSCC is cytotoxic and involves a bystander effect
We next determined whether all three cell lines examined expressed surface Coxsackie-adenovirus receptors (CAR). Using flow cytometry, we found that all cell lines expressed CAR with mean fluorescence of 33.96, 45.41, and 63.77 for SCC-14a, SCC-1, and SCC-12 respectively (Figure 2a) . Based on this, we then determined the FasL therapy of HNSCC S ElOjeimy et al sensitivity of the HNSCC lines to AdGFPFasL-infection. Cells were treated for 48 h at an MOI of 50 with either AdGFPFasL virus or control virus (AdGFP). Again, cytotoxicity was determined using the MTS assay. As shown in Figure 2b , all three cell lines were sensitive to AdGFPFasL as compared to control virus regardless of their Fas-sensitivity to CH-11. The negative control AdGFP displayed no killing, showing that viral transduction alone was not responsible for inducing apoptosis. One problem of cancer gene therapy is the issue of vector delivery to every tumor cell in order to achieve complete tumor eradication. This deficiency can be theoretically overcome if the therapy induces a bystander activity within the tumor bed. 14 To this end, we showed that in the HNSCC line SCC-14a, similar to what we have previously seen in our prostate cancer models, 14 AdGFPFasL infected cells produce apoptotic bodies and cellular debris. As seen in Figure 2c , this material is able to induce apoptosis in uninfected neighboring cells. The bystander killing mechanism is mediated through Fas/ FasL interaction because it is significantly inhibited if target cells are pretreated with the Fas neutralizing antibody ZB-4 ( Figure 2c ).
AdGFPFasL induces characteristics consistent with Fas-mediated apoptosis
Both morphological and biochemical analyses were performed to determine if treatment of HNSCC cells with AdGFPFasL was consistent with programmed cell death. First, we performed microscopy on SCC-14a incubated with 50 MOI AdGFPFasL or AdGFP. UV fluorescence in Figure 3a (bottom row) demonstrates viral transduction and GFP expression in both treatment conditions. In the top row, untreated and AdGFP treated cells appeared generally as a monolayer across the dish whereas AdGFPFasL treated cells (bottom row) were clumped and rounded displaying signs of an apoptotic morphology (Figure 3a) . To confirm apoptosis, SCC-1 cells were incubated with 50 MOI AdGFPFasL or AdGFP for 24 h and immunoblot analysis was performed on protein lysates. PARP cleavage from 116 to 85 kDa and caspase 9 cleavage from 47 to 37 kDa are indicative of apoptosis and were detected only in lysates from AdGFPFasL treated cells (Figure 3b ). Induction of apoptosis by AdGFPFasL has also been established in other CH-11 cancer resistant cells including prostate and bladder lines. 12, 17 AdGFPFasL leads to significant tumor regression in vivo Although the SCC-14a cell line appeared to be quite sensitive to apoptotic induction by AdGFPFasL, it was not clear if the cells would behave similarly in an in vivo environment. To address this, an experiment was initiated to compare the growth of SCC-14a cells with and without AdGFPFasL treatment over a period of 3 months. On the one hand, AdGFPFasL led to significant regression of the growing tumors as compared with the AdGFP treated and the nontreated mice (Po0.001). In addition, in tumors with complete regression, there was only a small scar left in the place of the tumor (Figure 4a ). On the other hand, 83% of mice treated with AdGFPFasL were still alive after 3-month follow-up as compared with 0% of AdGFP-treated and nontreated mice groups (Figure 4c) . Moreover, there were no signs of systemic toxicity associated with multiple orthotopic viral injection during this time period. 
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Discussion
Effective treatment of advanced head and neck cancer remains a challenge. Although advances in the utility of chemotherapy and combinations of chemoradiotherapy have shown improvements in efficacy and locoregional control when compared to radiation alone, survival improvements are controversial and toxicity remains significant. 18, 19 Tumor cell resistance limits the effective use of chemotherapy and radiation regimens for organ preservation and improved quality of life. In many cases, the option of surgery comes with serious quality of life issues and all treatments (chemotherapy, radiation therapy, surgery) can result in serious problems with speech, swallowing, chewing, and airway protection. 19 In fact, the combination of chemotherapy and radiation therapy can result in significantly increased morbidity and mortality. 18 Therefore, current treatment modalities are inadequate for many patients, and improved novel therapies and delivery mechanisms are necessary to reduce effects of increasing incidence and complications in HNSCC.
In this report, we have characterized the in vitro and in vivo efficacy of a FasL gene therapy based approach for the treatment of HNSCC. We have demonstrated extensive cytotoxicity following treatment with AdGFPFasL in HNSCC as compared with FasL antibody delivery. In addition, we have observed that variable plasma membrane levels of Fas receptors do not heavily impact the efficacy of adenoviral-based gene therapy strategies. The clinical implications of the model described in this paper are two-fold. First, the ease of access to HNSCC with gene therapy has led to the successful implementation of Adp53 gene therapy for HNSCC. 11 Other gene based therapies are also in clinical trials in HNSCC patients. 20, 21 However, in vivo cancer gene therapy approaches for HNSCC based on adenoviral vector mediated gene delivery have been limited by the suboptimal efficacy of gene transfer to tumor cells. The main problem of these approaches is the insufficient distribution of the gene therapy vehicles, mostly viruses, over the entire tumor. In our models, we show that inducing Fas-mediated apoptosis in HNSCC is a promising new therapeutic approach with the potential to overcome delivery issues currently problematic in cancer gene therapy. Our observed efficacy is hypothesized to be due to the bystander effect, previously shown by us in a prostate cancer model where AdGFPFasL-infected cancer cells release apoptotic and cellular debris capable of inducing FasL-mediated bystander killing in adjacent cancer cells. 14 Secondly, systemic delivery of FasL has proven to be toxic especially to the liver. Local intratumoral injection allowed us to avoid liver toxicity that would be associated with systemic delivery of AdGFPFasL. In our hands, mice sustained no observable adverse response during our preclinical trial. In addition, further studies of agents that act synergistically with FasL (chemotherapy or radiation), which are ongoing in our laboratory, may aid in decreasing the number of adenoviral particles injected in order to further reduce the potential for adverse effects while maintaining potency.
In conclusion, the data presented here demonstrate the efficacy of AdGFPFasL gene therapy in both in vitro and in vivo models. The observed bystander effect supports development of AdGFPFasL as a gene therapy agent. It is likely that gene transfer either alone or in combination with standard therapies may result in improved locoregional control and potentially survival in HNSCC. 
